

**American College of Radiology  
ACR Appropriateness Criteria®  
Renovascular Hypertension**

**Variant 1: High index of suspicion of renovascular hypertension. Normal renal function.**

Radiologic Procedure	Rating	Comments	RRL*
MRA abdomen without and with IV contrast	8		O
CTA abdomen with IV contrast	8		☼☼☼
US duplex Doppler kidneys retroperitoneal	7		O
MRA abdomen without IV contrast	5		O
ACE-inhibitor renography	5		☼☼☼
Arteriography kidney	3		☼☼☼
Venography with renal vein sampling	3		Varies
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 2: High index of suspicion of renovascular hypertension. Decreased renal function, eGFR <30 mL/min/1.73 m<sup>2</sup>.**

Radiologic Procedure	Rating	Comments	RRL*
US duplex Doppler kidneys retroperitoneal	9		O
MRA abdomen without IV contrast	7		O
CTA abdomen with IV contrast	5		☼☼☼
MRA abdomen without and with IV contrast	3		O
ACE-inhibitor renography	3		☼☼☼
Arteriography kidney	3		☼☼☼
Venography with renal vein sampling	3		Varies
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

## RENOVASCULAR HYPERTENSION

Expert Panels on Urologic Imaging and Vascular Imaging: Howard J. Harvin, MD<sup>a</sup>; Nupur Verma, MD<sup>b</sup>; Paul Nikolaidis, MD<sup>c</sup>; Michael Hanley, MD<sup>d</sup>; Vikram S. Dogra, MD<sup>e</sup>; Stanley Goldfarb, MD<sup>f</sup>; John L. Gore, MD<sup>g</sup>; Stephen J. Savage, MD<sup>h</sup>; Michael L. Steigner, MD<sup>i</sup>; Richard Strax, MD<sup>j</sup>; Myles T. Taffel, MD<sup>k</sup>; Jade J. Wong-You-Cheong, MD<sup>l</sup>; Don C. Yoo, MD<sup>m</sup>; Erick M. Remer, MD<sup>n</sup>; Karin E. Dill, MD<sup>o</sup>; Mark E. Lockhart, MD, MPH.<sup>p</sup>

### Summary of Literature Review

#### **Introduction/Background**

Hypertension is a common condition, affecting approximately 20% of adults. Secondary hypertension (ie, hypertension with a demonstrable cause) accounts for only 5% to 10% of all cases of hypertension, with the remaining cases considered primary hypertension or essential hypertension. Renovascular hypertension is the most common type of secondary hypertension and is estimated to have a prevalence between 0.5% and 5% of the general hypertensive population, and it has an even higher prevalence among patients with severe hypertension and end-stage renal disease, approaching 25% in elderly dialysis patients [1]. There are varied causes of reduced renal perfusion with resultant renovascular hypertension, the most common being renal artery stenosis (RAS) secondary to either atherosclerotic disease (90%) or fibromuscular dysplasia (10%) [2]. Less common etiologies include vasculitis, embolic disease, dissection, post-traumatic occlusion, and extrinsic compression of a renal artery or of a kidney [3]. Clinical features associated with an increased likelihood of renovascular hypertension include an abdominal bruit, malignant or accelerated hypertension, significant (diastolic pressure >110 mm Hg) hypertension in a young adult (<35 years of age), new onset after 50 years of age, sudden development or worsening of hypertension, refractory hypertension, deterioration of renal function in response to angiotensin-converting enzyme inhibitors, and generalized arteriosclerotic occlusive disease with hypertension.

A critical problem in diagnosing renovascular hypertension is the selection of an appropriate end point against which to judge the accuracy of new tests. Calculations of the sensitivity, specificity, and accuracy of these examinations are normally based on a comparison with a standard such as conventional angiography. However, the definition of a significant RAS has varied. Most investigators consider a 50% to 60% stenosis to be significant, yet perfusion pressure in a large artery is generally not reduced until stenosis exceeds 70% to 75%. Ultimately, the defining criterion for renovascular hypertension is a fall in blood pressure after intervention (angioplasty, intravascular stent placement, or surgery). Bilateral renal artery disease remains a problem in that it is difficult in such cases to quantify the effect on blood pressure of one side versus the other.

Testing for RAS is not appropriate for patients who have a low likelihood of renovascular hypertension. Investigation for renovascular hypertension is appropriate when the clinical presentation suggests secondary hypertension rather than primary hypertension, when there is not another known cause of secondary hypertension, and when intervention would be carried out if a significant RAS were identified. Recent investigation has directed the appropriateness of investigation for RAS. Specifically, the Cardiovascular Outcomes in Renal Atherosclerotic Lesions trial—a randomized controlled trial of 947 patients from 113 centers published in 2013—showed no difference in multiple end points between medical therapy and renal stenting in patients with atherosclerotic RAS and hypertension or chronic kidney disease [4]. The conclusion derived from this trial is that testing for RAS is not typically warranted for patients whose hypertension is well managed with medical therapy. Scenarios where testing for RAS may be warranted include new-onset hypertension, failure of antihypertensive medical therapy, progressive renal insufficiency suspected to be attributable to renovascular disease, episodes of flash pulmonary edema, and young patients with suspected fibromuscular dysplasia (for whom renal artery angioplasty may be

---

<sup>a</sup>Principal Author, Scottsdale Medical Imaging, Scottsdale, Arizona. <sup>b</sup>Co-author, University of Florida, Gainesville, Florida. <sup>c</sup>Panel Vice-Chair (Urologic), Northwestern University, Chicago, Illinois. <sup>d</sup>Panel Vice-Chair (Vascular), University of Virginia Health System, Charlottesville, Virginia. <sup>e</sup>University of Rochester Medical Center, Rochester, New York. <sup>f</sup>University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; American Society of Nephrology. <sup>g</sup>University of Washington, Seattle, Washington; American Urological Association. <sup>h</sup>Medical University of South Carolina, Charleston, South Carolina; American Urological Association. <sup>i</sup>Brigham & Women's Hospital, Boston, Massachusetts. <sup>j</sup>Baylor College of Medicine, Houston, Texas. <sup>k</sup>George Washington University Hospital, Washington, District of Columbia. <sup>l</sup>University of Maryland School of Medicine, Baltimore, Maryland. <sup>m</sup>Rhode Island Medical Imaging Inc., East Providence, Rhode Island. <sup>n</sup>Specialty Chair (Urologic), Cleveland Clinic, Cleveland, Ohio. <sup>o</sup>Panel Chair (Vascular), UMass Memorial Medical Center, Worcester, Massachusetts. <sup>p</sup>Panel Chair (Urologic), University of Alabama at Birmingham, Birmingham, Alabama.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: [publications@acr.org](mailto:publications@acr.org)

preferable to long-term medical therapy) [3,5]. Given the limited scenarios in which testing for renovascular hypertension is considered appropriate, the decision to perform diagnostic imaging to identify RAS should ideally be based on a multidisciplinary assessment of an individual patient's clinical presentation and comorbidities, and the likelihood of response to intervention [5].

### **Overview of Imaging Modalities**

Ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), scintigraphy, and angiography all may be utilized in the diagnosis of RAS. Intravenous urography for RAS is of historical note [6] and is no longer used as a screening test. US can be utilized regardless of level of renal function. Contrast-enhanced CT angiography (CTA) and MR angiography (MRA) are both effective modalities for diagnosis of RAS, though both have been associated with potential morbidity in the setting of impaired renal function—nephrogenic systemic fibrosis (NSF) in the case of MRI and contrast material–induced nephropathy (CIN) in the case of CT [7]. Noncontrast MRI protocols are an alternative in patients with impaired renal function. The association between intravenous contrast material for CT and development of acute kidney injury has come under question, and recent data indicate that there is a much lower risk of CIN than was previously thought [8]. In addition to identification of RAS, CT, MRI, and, to a lesser extent, US can also assess for aortic disease, accessory renal arteries, some forms of renal parenchymal disease, and other causes of secondary hypertension such as pheochromocytomas. Renal scintigraphy also can be utilized for the diagnosis of RAS but has decreased accuracy in patients with bilateral RAS or impaired renal function. Angiography is predominantly used for confirmation and intervention rather than screening for RAS.

### **Discussion of Procedures by Variant**

#### **Variant 1: High index of suspicion of renovascular hypertension. Normal renal function.**

##### **US**

Duplex Doppler US is an attractive technique as a noninvasive screening test in that it does not require intravenous contrast material and can be used in patients with any level of renal function. As with many of the noninvasive imaging examinations, there are numerous parameters and abnormal criteria indicating possible renovascular disease.

Two of the most frequently used parameters are peak systolic velocity (PSV) in the main renal artery and renal artery to aortic systolic ratio (RAR), both of which depend on a direct evaluation of elevated velocity in a stenotic segment of the renal artery. PSV cutoff values ranging from 180 cm/s to 300 cm/s have been proposed in various studies. Hua et al [9] showed a PSV of 200 cm/s to have a sensitivity of 91% and a specificity of 75%, whereas Motew et al [10] reported a PSV of 200 cm/s to have a sensitivity of 91% and a specificity of 96% and AbuRahma et al [11] reported a PSV of 200 cm/s to have a sensitivity of 73% and specificity of 82% for stenosis  $\geq 60\%$ . To improve specificity, some authors recommend a higher PSV threshold of 300 cm/s [3].

An elevated RAR value is also a useful criterion for identifying stenosis, because PSV may be elevated on the basis of hypertension without underlying RAS. The suggested RAR cutoff value also varies between authors, though an RAR of 3.5 is a commonly reported threshold value [12]. It is noted that identification of elevated PSV and RAR depends on adequate visualization of a stenotic segment of the renal artery, which may be impeded by patient body habitus, obscuring bowel gas, dense atherosclerotic plaques, and presence of accessory renal arteries. In these cases, distal criteria may be useful as an indirect indicator of stenosis. A parvus-tardus intrarenal waveform, with a small peak and a slow upstroke, is highly suggestive of a proximal stenosis [13]. This is reflected by an acceleration time of  $>70$  milliseconds and loss of the early systolic peak. Though an elevated resistive index (RI), defined as  $(\text{PSV} - \text{end-diastolic velocity})/\text{PSV}$ , is not a specific indicator of RAS, an RI  $>0.80$  has been reported to be a negative prognostic sign for response to revascularization [14,15]. However, other studies have not confirmed a significant difference in revascularization outcomes according to RI and have argued against using an elevated RI as a contraindication to revascularization [16,17].

Doppler US can also be used for detection of significant renal artery in-stent restenosis, though studies have shown that compared with native renal arteries, higher PSV and RAR values are indicative of stenosis in stented arteries. Chi et al [18], in a study of 67 patients with renal artery stents, found that a PSV of at least 395 cm/s or RAR of at least 5.1 was most predictive of significant in-stent stenosis. Similarly, Del Conde et al [19], in a study of 132 stented renal arteries, reported a mean PSV of 382 cm/s and RAR of 5.3 in arteries with  $>60\%$  stenosis.

Although Doppler US is a preferred screening tool for RAS, it is time-consuming and highly operator dependent, and MRI or CT may be more reliable modalities for operators who are less experienced with US for RAS.

### **Nuclear Medicine**

Renal scintigraphy was first used for evaluating renal function in the late 1950s. Initial attempts to use renography specifically for evaluating renovascular hypertension had a high rate of false-positive and false-negative results. Captopril was later added to the examination in an attempt to improve the accuracy of the test for diagnosing renovascular hypertension and for predicting blood pressure reduction after surgery or angioplasty. Administration of an angiotensin-converting enzyme inhibitor such as captopril leads to a decrease in glomerular filtration pressure, prolonged transit time of tubular agents such as Tc-99m-MAG3, and decreased uptake of glomerular agents such as Tc-99m-diethylenetriaminepentaacetic acid.

Captopril renal scintigraphy analysis is based on characterization of renal function deterioration when compared with a baseline study, with decreased glomerular filtration rate reflected in time-activity curves. Captopril renography is therefore a functional assessment of renal perfusion and function rather than a method of directly visualizing the vasculature. The sensitivity and specificity of this examination are decreased in patients without clinical features of renovascular hypertension and are also decreased in patients with bilateral RAS, impaired renal function, and urinary obstruction [20]. The reported sensitivity of captopril renal scintigraphy for renovascular hypertension ranges from 34% to 93%, with a meta-analysis of 14 studies between 1990 and 2000 by Vasbinder et al [21] showing a mean sensitivity of approximately 81%. There have also been inconsistent results regarding the predictive value of captopril renal scintigraphy in identifying patients who will respond to revascularization. High correlation between a positive result on captopril renal scintigraphy and reduction in blood pressure after intervention has been reported in some studies [22]. However, the predictive value has been dismissed in other studies, with reported positive predictive values as low as 51% [23-26].

In summary, captopril renal scintigraphy has decreased sensitivity and specificity in patients with bilateral stenosis and impaired renal function, but it can be a useful tool for detecting renovascular hypertension in appropriately selected patients. As a functional evaluation of renal perfusion and function, captopril scintigraphy can be useful to determine the physiologic sequence of a known stenosis and to assess the relative function of each kidney before intervention [27,28].

### **MRA**

MRA is suited for noninvasive workup of RAS and has been widely applied in clinical practice. The reliability of MRA is not affected by the presence of bilateral renovascular disease. It is unnecessary to hydrate the patients or to stop diuretics before the examination. Three-dimensional contrast-enhanced MRA with an intravenous injection of gadolinium-based contrast agent has been the backbone of MRI examinations of renal arteries, but noncontrast MRA with steady-state free precession (SSFP) and arterial spin labeling techniques has also been used for evaluating the renal arteries.

Several investigators report using angiography as the standard of reference, with the sensitivity of MRA ranging from 88% to 100% and the specificity ranging from 71% to 100% [29-31]. In a meta-analysis of 25 studies [32], the sensitivity and specificity of gadolinium-enhanced MRA were 97% and 85%, respectively. Solar et al [33] compared contrast-enhanced MRA with Doppler US using angiography as the reference and found contrast-enhanced MRA to be superior, with a sensitivity of 93% and a specificity of 93%, compared with US, with a sensitivity of 85% and a specificity of 84%. With the use of high-spatial-resolution small-field-of-view contrast-enhanced MRA techniques, it is possible to evaluate not only the main renal arteries but also the accessory renal arteries and distal stenosis. Improved gradient hardware and parallel imaging techniques have reduced acquisition times and improved spatial resolution. Another MR technique currently being investigated, blood oxygen level-dependent MRI, is able to assess renal oxygenation, which may allow for functional assessment in patients with RAS [34-36]. MRA may be used to evaluate in-stent stenosis and has been especially successful when nonferromagnetic stents such as platinum, nitinol, or cobalt-chromium are used, as compared with stainless steel stents [37-39].

### **CTA**

Contrast-enhanced CTA provides accurate anatomic images of the renal arteries with isotropic data sets that enable the reconstruction of high-resolution images in any plane. As with conventional angiography, the disadvantages of this technique are its ionizing radiation and its use of nephrotoxic contrast material. Advantages compared with arteriography include less invasiveness, faster acquisitions, and multiplanar imaging [40]. Two

studies comparing CTA with digital renal arteriography have reported the sensitivity of CTA for detecting stenoses (>50% diameter) to be 88% to 96% and the specificity to be 77% to 98%, and in one study the accuracy was 89%. In diagnosing narrowing of only the main renal arteries, one study found the sensitivity and specificity to be 100% and 98%, respectively [41,42]. Normal results from CTA virtually rule out RAS. Both maximum-intensity projection and volume-rendering techniques are useful and complementary in CT evaluation of RAS [43]. Secondary signs include poststenotic dilatation, renal atrophy, and decreased cortical enhancement. A threshold of 800 mm<sup>2</sup> for cortical area and 8 mm for mean cortical thickness seen on CT can be useful morphologic markers of atherosclerotic renal disease [44].

Like MRA, CTA is more accurate in diagnosing proximal rather than distal lesions, though in general CTA provides better depiction of branch renal arteries than MRA [45]. CTA can also be used to assess patency of renal stents [44,46,47]. Steinwender et al [48] described CTA evaluation of 95 renal artery stents in which 98% of the stents were assessable on CTA, and there was 100% sensitivity and 99% specificity for detecting in-stent stenosis.

### **Arteriography**

Intra-arterial digital subtraction angiography (IADSA) is considered the reference standard for demonstrating RAS and is an integral part of angioplasty and stenting procedures. Angiography has high spatial resolution for evaluating the main renal arteries as well as the branch renal arteries. There is high interobserver agreement for identification of severe stenoses by angiography [49], but there is reported substantial interobserver variability in visual estimation of moderate RAS. IADSA allows for measurement of pressure gradients across a stenosis, providing assessment of its hemodynamic significance before intervention. A pressure gradient >20 mm Hg, or >10% of mean arterial pressure, is considered to be an indicator of hemodynamic significance [50,51].

Smith et al [52], in a small study of 19 patients, reported the sensitivity and specificity of intravenous digital subtraction angiography (IVDSA) to be as high as 87%. However, false-positive rates ranged from 26% to 37%, which they attributed to limited spatial resolution, subtraction artifacts, and quantum noise. Other reported limitations of this technique have included obscuration of renal artery stenoses by overlap with opacified mesenteric vessels and also suboptimal evaluation of fibromuscular lesions [53-55]. Wilms et al [55], in a study of 45 patients, found fewer false-positives, which they attributed to technical advances and software improvements. They also reported that IVDSA grading of stenosis was accurate in 94% of cases of atherosclerotic RAS but in only 56% of fibromuscular stenosis cases. Dunnick et al [56], in a prospective study of 94 patients, reported 100% sensitivity and 93% specificity for RAS, though the 100% sensitivity was achieved in part by including inadequate examinations as positive, and the authors acknowledged the limitations of IVDSA for evaluating vessels affected by fibromuscular dysplasia. Although good results can be achieved with IVDSA, its resolution is inferior compared with that of IADSA, and it is less sensitive than IADSA for evaluating fibromuscular dysplasia and atherosclerotic stenosis of branch vessels. In addition, the contrast dose is often substantially higher than in arteriography and requires central injection in the inferior vena cava or right atrium. For these reasons, IVDSA is not utilized as a screening examination for renovascular hypertension.

### **Venography**

In patients with unilateral RAS, the ischemic kidney secretes increased renin, and there is relative suppression of renin release by the contralateral kidney. This results in asymmetry in renal vein renin levels. With bilateral RAS, there is also lateralization of renin secretion, with higher renal vein renin for the kidney with the greater degree of stenosis. This is the basis for renal vein renin assays for evaluation of renovascular hypertension. Various parameters have been described, including renal vein-to-inferior vena cava ratios and right renal vein-to-left renal vein ratios. Renal vein renin assays were initially considered the best means to predict response to revascularization in patients with suspected renovascular hypertension, with the majority of studies before 1980 supporting the validity of this procedure. However, later studies have shown a high rate of false-negative and false-positive results. Sellars et al [57] reviewed 37 cases and found a false-positive rate of 39% and a false-negative rate of 71%. Luscher et al [58], in a study involving 95 patients, reported a high sensitivity of 92% for a positive renal vein renin assay but a low specificity of 42% and a high number of both false-positive and false-negative results. Roubidoux et al [59] measured captopril-stimulated renal vein renin ratios in 133 patients and found a sensitivity of 65%, a false-positive rate of 47.8%, a positive predictive value of 18.6%, and a negative predictive value of 89.3%. Postma et al [25], in a retrospective study of 25 patients with documented RAS, found that a positive renal vein renin assay had a sensitivity of 72% and a specificity of only 29%. In general, the high rates of false-negative and false-positive studies limit the use of renal vein renin assays as screening tests for renovascular hypertension.

**Variant 2: High index of suspicion of renovascular hypertension. Decreased renal function, eGFR <30 mL/min/1.73 m<sup>2</sup>.**

The selection of imaging modality and technique for evaluation of RAS may vary in the setting of decreased renal function primarily because of the risk of CIN with iodinated contrast material for CT and the risk of NSF with gadolinium-based contrast agents for MRI.

**US**

For patients with a high index of suspicion for renovascular disease and diminished renal function, duplex Doppler US is a preferred screening examination, especially at a site where the technique has proven to be reliable and where dedicated technologists and physicians are skilled in the examination and can perform it with a high degree of accuracy. The technical details of the examination and the threshold criteria are similar to those used for patients with normal renal function (see variant 1).

**CTA**

Depending on the degree of impaired renal function, contrast-enhanced CTA has been considered to be precluded because of potential nephrotoxicity of contrast material. However, the causal relationship between contrast material for CT and acute kidney injury has been disputed, and recent data suggest a low risk of clinically relevant CIN. Cutoff values for serum creatinine and estimated glomerular filtration rate (eGFR) beyond which iodinated contrast material would not be administered vary by institution, though eGFR is recognized to be a better indicator of baseline renal function than serum creatinine. Recent large studies from Davenport et al in 2013 and McDonald et al in 2014 indicate that intravenous iodinated contrast material is not an independent nephrotoxic risk factor in patients with a stable baseline eGFR of >45 mL/min/1.73 m<sup>2</sup> and that iodinated contrast material is rarely nephrotoxic in patients with a stable baseline eGFR of 30 to 44 mL/min/1.73 m<sup>2</sup> [60-63]. Conflicting results were obtained for patients with more severe renal dysfunction with an eGFR of <30 mL/min/1.73 m<sup>2</sup>, with the 2013 Davenport et al study reporting an excess of acute kidney injury in these patients receiving intravenous contrast material versus controls but with the 2014 McDonald et al study showing no significant difference in acute kidney injury for contrast material recipients versus control patients with this baseline eGFR [8,60-63]. The *ACR Manual on Contrast Media* notes that if a threshold for CIN risk is used, an eGFR of 30 mL/min/1.73 m<sup>2</sup> has the greatest level of evidence [7]. Reduced iodine dose should be considered in patients with borderline renal function, but other parameters are similar to patients with normal renal function. Unenhanced CT does not provide useful diagnostic information regarding RAS.

**MRA**

Contrast-enhanced MRA may be precluded because of the risk of NSF with eGFR <30 mL/min/1.73 m<sup>2</sup>. In these patients, unenhanced MRA techniques are available as an alternative to contrast-enhanced MRA to avoid the risk of NSF. Utsunomiya et al [64], comparing unenhanced SSFP MRA with CT or IADSA in 26 patients, found a sensitivity, specificity, positive predictive value, and negative predictive value of 78%, 91%, 64%, and 96%, respectively. Mohrs et al [65], comparing an SSFP technique with contrast-enhanced MRA in 45 patients, found a sensitivity, specificity, positive predictive value, and negative predictive value of 75%, 99%, 75%, and 99%, respectively, for detecting renal artery stenoses >50%. Braidy et al [66] compared an unenhanced SSFP technique to contrast-enhanced MRA with a sensitivity, specificity, positive predictive value, and negative predictive value of 85%, 96%, 94%, and 96%, respectively, but emphasized that when stenosis is found, other modalities should be employed for better estimation. Albert et al [67], in a report of a multicenter trial of 75 patients, compared an unenhanced MRA technique to contrast-enhanced CT with a sensitivity of 74% and specificity of 93% for >50% stenosis.

**Arteriography and Venography**

Impaired renal function may also limit the use of iodinated contrast material for angiography-based interventional procedures. Carbon dioxide, supplemented by limited use of gadolinium-based agents when mild to moderate decreased function allows, have both been used as alternatives to iodinated contrast in patients for whom iodinated contrast is contraindicated, though images obtained with these alternative contrast agents are less desirable when compared with those obtained with iodinated contrast material [68,69].

**Nuclear Medicine**

Captopril renal scintigraphy is not a reliable test in patients with poor renal function.

## Summary of Recommendations

- Given the limited scenarios in which testing for RAS is considered appropriate, the decision to perform diagnostic imaging to identify RAS should ideally be based on a multidisciplinary assessment of an individual patient’s clinical presentation, comorbidities, and likelihood of response to intervention.
- For patients with normal renal function, contrast-enhanced CTA and MRA are preferred modalities. US is also an effective modality.
- For patients with decreased renal function with eGFR <30 mL/min/1.73 m<sup>2</sup>, US is a preferred screening examination. Unenhanced MRA techniques are available as an alternative to contrast-enhanced MRA to avoid the risk of NSF in these patients.

## Summary of Evidence

Of the 70 references cited in the *ACR Appropriateness Criteria® Renovascular Hypertension* document, 2 are categorized as therapeutic references including 1 well-designed study. Additionally, 66 references are categorized as diagnostic references including 5 well-designed studies, 15 good-quality studies, and 16 quality studies that may have design limitations. There are 31 references that may not be useful as primary evidence. There are 2 references that are meta-analysis studies.

The 70 references cited in the *ACR Appropriateness Criteria® Renovascular Hypertension* document were published from 1964 to 2017.

Although there are references that report on studies with design limitations, 21 well-designed or good-quality studies provide good evidence.

## Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the *ACR Appropriateness Criteria® Radiation Dose Assessment Introduction* document [70].

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊕	<0.1 mSv	<0.03 mSv
⊕⊕	0.1-1 mSv	0.03-0.3 mSv
⊕⊕⊕	1-10 mSv	0.3-3 mSv
⊕⊕⊕⊕	10-30 mSv	3-10 mSv
⊕⊕⊕⊕⊕	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

## Supporting Documents

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

## References

1. O'Neill WC, Bardelli M, Yevzlin AS. Imaging for renovascular disease. *Semin Nephrol.* 2011;31(3):272-282.
2. Baumgartner I, Lerman LO. Renovascular hypertension: screening and modern management. *Eur Heart J.* 2011;32(13):1590-1598.
3. Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. *Am J Hypertens.* 2010;23(11):1159-1169.
4. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. *N Engl J Med.* 2014;370(1):13-22.
5. Herrmann SM, Saad A, Textor SC. Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL). *Nephrol Dial Transplant.* 2015;30(3):366-375.
6. Maxwell MH, Gonick HC, Wiita R, Kaufman JJ. Use of the Rapid-Sequence Intravenous Pyelogram in the Diagnosis of Renovascular Hypertension. *N Engl J Med.* 1964;270:213-220.
7. American College of Radiology. *Manual on Contrast Media.* Available at: <http://www.acr.org/Quality-Safety/Resources/Contrast-Manual>. Accessed March 1, 2016.
8. McDonald RJ, McDonald JS, Newhouse JH, Davenport MS. Controversies in Contrast Material-induced Acute Kidney Injury: Closing in on the Truth? *Radiology.* 2015;277(3):627-632.
9. Hua HT, Hood DB, Jensen CC, Hanks SE, Weaver FA. The use of colorflow duplex scanning to detect significant renal artery stenosis. *Ann Vasc Surg.* 2000;14(2):118-124.
10. Motew SJ, Cherr GS, Craven TE, et al. Renal duplex sonography: main renal artery versus hilar analysis. *J Vasc Surg.* 2000;32(3):462-469; 469-471.
11. AbuRahma AF, Srivastava M, Mousa AY, et al. Critical analysis of renal duplex ultrasound parameters in detecting significant renal artery stenosis. *J Vasc Surg.* 2012;56(4):1052-1059, 1060 e1051; discussion 1059-1060.
12. Labropoulos N, Ayuste B, Leon LR, Jr. Renovascular disease among patients referred for renal duplex ultrasonography. *J Vasc Surg.* 2007;46(4):731-737.
13. Li JC, Yuan Y, Qin W, et al. Evaluation of the tardus-parvus pattern in patients with atherosclerotic and nonatherosclerotic renal artery stenosis. *J Ultrasound Med.* 2007;26(4):419-426.
14. Radermacher J. Echo-doppler to predict the outcome for renal artery stenosis. *J Nephrol.* 2002;15 Suppl 6:S69-76.
15. Viazzi F, Leoncini G, Derchi LE, Pontremoli R. Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient. *J Hypertens.* 2014;32(1):149-153.
16. Garcia-Criado A, Gilabert R, Nicolau C, et al. Value of Doppler sonography for predicting clinical outcome after renal artery revascularization in atherosclerotic renal artery stenosis. *J Ultrasound Med.* 2005;24(12):1641-1647.
17. Krumme B, Hollenbeck M. Doppler sonography in renal artery stenosis--does the Resistive Index predict the success of intervention? *Nephrol Dial Transplant.* 2007;22(3):692-696.
18. Chi YW, White CJ, Thornton S, Milani RV. Ultrasound velocity criteria for renal in-stent restenosis. *J Vasc Surg.* 2009;50(1):119-123.
19. Del Conde I, Galin ID, Trost B, et al. Renal artery duplex ultrasound criteria for the detection of significant in-stent restenosis. *Catheter Cardiovasc Interv.* 2014;83(4):612-618.
20. Soulez G, Oliva VL, Turpin S, Lambert R, Nicolet V, Therasse E. Imaging of renovascular hypertension: respective values of renal scintigraphy, renal Doppler US, and MR angiography. *Radiographics.* 2000;20(5):1355-1368; discussion 1368-1372.
21. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. *Ann Intern Med.* 2001;135(6):401-411.
22. Geyskes GG, de Bruyn AJ. Captopril renography and the effect of percutaneous transluminal angioplasty on blood pressure in 94 patients with renal artery stenosis. *Am J Hypertens.* 1991;4(12 Pt 2):685S-689S.
23. Bolduc JP, Oliva VL, Therasse E, et al. Diagnosis and treatment of renovascular hypertension: a cost-benefit analysis. *AJR Am J Roentgenol.* 2005;184(3):931-937.
24. Huot SJ, Hansson JH, Dey H, Concato J. Utility of captopril renal scans for detecting renal artery stenosis. *Arch Intern Med.* 2002;162(17):1981-1984.
25. Postma CT, van Oijen AH, Barentsz JO, et al. The value of tests predicting renovascular hypertension in patients with renal artery stenosis treated by angioplasty. *Arch Intern Med.* 1991;151(8):1531-1535.



26. Soulez G, Therasse E, Qanadli SD, et al. Prediction of clinical response after renal angioplasty: respective value of renal Doppler sonography and scintigraphy. *AJR Am J Roentgenol*. 2003;181(4):1029-1035.
27. Bongers V, Bakker J, Beutler JJ, Beek FJ, De Klerk JM. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. *Clin Radiol*. 2000;55(5):346-353.
28. Taylor A. Renovascular hypertension: nuclear medicine techniques. *Q J Nucl Med*. 2002;46(4):268-282.
29. Kramer U, Wiskirchen J, Fenchel MC, et al. Isotropic high-spatial-resolution contrast-enhanced 3.0-T MR angiography in patients suspected of having renal artery stenosis. *Radiology*. 2008;247(1):228-240.
30. McGregor R, Vymazal J, Martinez-Lopez M, et al. A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease. *Eur J Radiol*. 2008;65(2):316-325.
31. Soulez G, Pasowicz M, Benea G, et al. Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR angiography--comparison with DSA. *Radiology*. 2008;247(1):273-285.
32. Tan KT, van Beek EJ, Brown PW, van Delden OM, Tijssen J, Ramsay LE. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. *Clin Radiol*. 2002;57(7):617-624.
33. Solar M, Zizka J, Krajina A, et al. Comparison of duplex ultrasonography and magnetic resonance imaging in the detection of significant renal artery stenosis. *Acta Medica (Hradec Kralove)*. 2011;54(1):9-12.
34. Gloviczki ML, Lerman LO, Textor SC. Blood oxygen level-dependent (BOLD) MRI in renovascular hypertension. *Curr Hypertens Rep*. 2011;13(5):370-377.
35. Gloviczki ML, Saad A, Textor SC. Blood oxygen level-dependent (BOLD) MRI analysis in atherosclerotic renal artery stenosis. *Curr Opin Nephrol Hypertens*. 2013;22(5):519-524.
36. Niendorf T, Pohlmann A, Arakelyan K, et al. How bold is blood oxygenation level-dependent (BOLD) magnetic resonance imaging of the kidney? Opportunities, challenges and future directions. *Acta Physiol (Oxf)*. 2015;213(1):19-38.
37. Wang Y, Truong TN, Yen C, et al. Quantitative evaluation of susceptibility and shielding effects of nitinol, platinum, cobalt-alloy, and stainless steel stents. *Magn Reson Med*. 2003;49(5):972-976.
38. Buecker A, Spuentrup E, Ruebben A, Gunther RW. Artifact-free in-stent lumen visualization by standard magnetic resonance angiography using a new metallic magnetic resonance imaging stent. *Circulation*. 2002;105(15):1772-1775.
39. Spuentrup E, Ruebben A, Stuber M, Gunther RW, Buecker A. Metallic renal artery MR imaging stent: artifact-free lumen visualization with projection and standard renal MR angiography. *Radiology*. 2003;227(3):897-902.
40. Willmann JK, Wildermuth S, Pfammatter T, et al. Aortoiliac and renal arteries: prospective intraindividual comparison of contrast-enhanced three-dimensional MR angiography and multi-detector row CT angiography. *Radiology*. 2003;226(3):798-811.
41. Beregi JP, Elkohen M, Deklunder G, Artaud D, Couillet JM, Wattinne L. Helical CT angiography compared with arteriography in the detection of renal artery stenosis. *AJR Am J Roentgenol*. 1996;167(2):495-501.
42. Farres MT, Lammer J, Schima W, et al. Spiral computed tomographic angiography of the renal arteries: a prospective comparison with intravenous and intraarterial digital subtraction angiography. *Cardiovasc Intervent Radiol*. 1996;19(2):101-106.
43. Berg MH, Manninen HI, Vanninen RL, Vainio PA, Soimakallio S. Assessment of renal artery stenosis with CT angiography: usefulness of multiplanar reformation, quantitative stenosis measurements, and densitometric analysis of renal parenchymal enhancement as adjuncts to MIP film reading. *J Comput Assist Tomogr*. 1998;22(4):533-540.
44. Mounier-Vehier C, Lions C, Devos P, et al. Cortical thickness: an early morphological marker of atherosclerotic renal disease. *Kidney Int*. 2002;61(2):591-598.
45. Francois CJ. Noninvasive imaging workup of patients with vascular disease. *Surg Clin North Am*. 2013;93(4):741-760, vii.
46. Mallouhi A, Rieger M, Czermak B, Freund MC, Waldenberger P, Jaschke WR. Volume-rendered multidetector CT angiography: noninvasive follow-up of patients treated with renal artery stents. *AJR Am J Roentgenol*. 2003;180(1):233-239.
47. Lufft V, Hoogestraat-Lufft L, Fels LM, et al. Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. *Am J Kidney Dis*. 2002;40(2):236-242.

48. Steinwender C, Schutzenberger W, Fellner F, et al. 64-Detector CT angiography in renal artery stent evaluation: prospective comparison with selective catheter angiography. *Radiology*. 2009;252(1):299-305.
49. van Jaarsveld BC, Pieterman H, van Dijk LC, et al. Inter-observer variability in the angiographic assessment of renal artery stenosis. DRASTIC study group. Dutch Renal Artery Stenosis Intervention Cooperative. *J Hypertens*. 1999;17(12 Pt 1):1731-1736.
50. De Bruyne B, Manoharan G, Pijls NH, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. *J Am Coll Cardiol*. 2006;48(9):1851-1855.
51. Mangiacapra F, Trana C, Sarno G, et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. *Circ Cardiovasc Interv*. 2010;3(6):537-542.
52. Smith CW, Winfield AC, Price RR, et al. Evaluation of digital venous angiography for the diagnosis of renovascular hypertension. *Radiology*. 1982;144(1):51-54.
53. Illescas FF, Ford K, Braun SD, Dunnick NR. Intraarterial digital subtraction angiography in hypertensive azotemic patients. *AJR Am J Roentgenol*. 1984;143(5):1065-1067.
54. Norman D, Ulloa N, Brant-Zawadzki M, Gould RG. Intraarterial digital subtraction imaging cost considerations. *Radiology*. 1985;156(1):33-35.
55. Wilms GE, Baert AL, Staessen JA, Amery AK. Renal artery stenosis: evaluation with intravenous digital subtraction angiography. *Radiology*. 1986;160(3):713-715.
56. Dunnick NR, Svetkey LP, Cohan RH, et al. Intravenous digital subtraction renal angiography: use in screening for renovascular hypertension. *Radiology*. 1989;171(1):219-222.
57. Sellars L, Shore AC, Wilkinson R. Renal vein renin studies in renovascular hypertension--do they really help? *J Hypertens*. 1985;3(2):177-181.
58. Luscher TF, Greminger P, Kuhlmann U, Siegenthaler W, Largiader F, Vetter W. Renal vein renin determinations in renovascular hypertension. Diagnostic and prognostic value in unilateral renal artery stenosis treated by surgery or percutaneous transluminal angioplasty. *Nephron*. 1986;44 Suppl 1:17-24.
59. Roubidoux MA, Dunnick NR, Klotman PE, et al. Renal vein renins: inability to predict response to revascularization in patients with hypertension. *Radiology*. 1991;178(3):819-822.
60. Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. *Radiology*. 2013;268(3):719-728.
61. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. *Radiology*. 2013;267(1):94-105.
62. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. *Radiology*. 2014;271(1):65-73.
63. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? *Radiology*. 2013;267(1):106-118.
64. Utsunomiya D, Miyazaki M, Nomitsu Y, et al. Clinical role of non-contrast magnetic resonance angiography for evaluation of renal artery stenosis. *Circ J*. 2008;72(10):1627-1630.
65. Mohrs OK, Petersen SE, Schulze T, et al. High-resolution 3D unenhanced ECG-gated respiratory-navigated MR angiography of the renal arteries: comparison with contrast-enhanced MR angiography. *AJR Am J Roentgenol*. 2010;195(6):1423-1428.
66. Braidly C, Daou I, Diop AD, et al. Unenhanced MR angiography of renal arteries: 51 patients. *AJR Am J Roentgenol*. 2012;199(5):W629-637.
67. Albert TS, Akahane M, Parienty I, et al. An international multicenter comparison of time-SLIP unenhanced MR angiography and contrast-enhanced CT angiography for assessing renal artery stenosis: the renal artery contrast-free trial. *AJR Am J Roentgenol*. 2015;204(1):182-188.
68. Caridi JG, Stavropoulos SW, Hawkins IF, Jr. CO<sub>2</sub> digital subtraction angiography for renal artery angioplasty in high-risk patients. *AJR Am J Roentgenol*. 1999;173(6):1551-1556.
69. Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, McGraw JK, Ayers C. Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO<sub>2</sub>-enhanced renal angiography for diagnosis and percutaneous treatment. *Radiology*. 1999;210(3):663-672.
70. American College of Radiology. ACR Appropriateness Criteria<sup>®</sup> Radiation Dose Assessment Introduction. Available at: <http://www.acr.org/~media/ACR/Documents/AppCriteria/RadiationDoseAssessmentIntro.pdf>. Accessed March 1, 2017.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.